Halozyme Therapeutics (HALO) shares were down over 24% in recent Tuesday trading after Leerink Partners downgraded the stock to underperform from market perform.
Trading volume was more than 10 million shares, compared with a daily average of about 1.8 million.
Price: 50.23, Change: -16.35, Percent Change: -24.55